Cashing COVID-19 Vaccine - AstraZeneca Or Pfizer

Today AstraZeneca plc AZN released its second-quarter earnings with updated sales numbers for its COVID-19 vaccine; when compared to the big mRNA players, the numbers looked rather pale.

Q2 Sales Numbers: AstraZeneca's COVID-19 jab clocked in about $1.17 billion globally in the first half, including $894 million in the second quarter alone

Pfizer Inc's PFE vaccine sales have soared with $3.5 billion in Q1 and another $7.8 billion in the second quarterModerna Inc MRNA, which is slated to report its second-quarter results next week, bagged $1.7 billion in COVID-19 vaccine sales in Q1.

Pfizer's sales jump has encouraged it to raise full-year projections to $33.5 billion, up from $26 billion in May and $15 billion in February. 

Let's Compare the Prices: Last week, when the U.S. called for additional 200 million doses of the Pfizer vaccine, it paid about $24/dose, up from the $19.50 in its earlier deals to supply. However, AstraZeneca is selling its vaccines at cost to low- and middle-income countries, which is a potential basis for the Company to decline to disclose full-year projections for its shot. 

In one example, AZN sold its shots to South Africa at $5.25 per dose, while Pfizer charged about $10 per dose. Albert Bourla wrote in a letter to employees, some lower-income countries didn't even bother ordering or authorizing the Pfizer vaccine at all, with the majority reserved by high-income nations.

Additionally, AstraZeneca's vaccine is still not authorized in the U.S. following safety issues and a dispute over efficacy data. But CEO Pascal Soriot appears to have gotten the ball rolling outside the U.S. in recent months. 

Recent real-world data from Canada showed similar levels in reducing severe illness, hospitalizations, and deaths to the mRNA shots. Also, a person's risk of blood clots does not increase after the second AZN COVID-19 vaccine shot.

AstraZeneca confirmed in its earnings call that it would be seeking a full FDA approval for its vaccine in the U.S. rather than shoot for an emergency use authorization. 

Soriot also took a contrasting position with Bourla on booster shots, telling a CNBC Europe, the Company did not have a "precise answer" on whether a booster would be required.

Price Action: AZN shares are up 1.50% at press time, while PFE shares are down 1.55% on Thursday.

Photo by Johaehn from Pixabay

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!